Docosahexaenoic acid enhances the treatment efficacy for castration-resistant prostate cancer by inhibiting autophagy through Atg4B inhibition
Archives of Biochemistry and Biophysics · 2024
DOI: 10.1016/j.abb.2024.110135 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Biochemistry and Biophysics, 2024. Verfasst von Yudai Kudo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Biochemistry, Department of Biopharmaceutical Sciences, Gifu Pharmaceutical University, Gifu, 501-1196, Japan. Hauptthemen laut MEDLINE: Docosahexaenoic Acids, Autophagy, Prostatic Neoplasms, Castration-Resistant, Autophagy-Related Proteins. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Autophagy induction in cancer is involved in cancer progression and the acquisition of resistance to anticancer agents. Therefore, autophagy is considered a potential therapeutic target in cancer therapy. In this study, we found that long-chain fatty acids (LCFAs) have inhibitory effects on Atg4B, which is essential for autophagosome formation, through screening based on the pharmacophore of 21f, a recently developed Atg4B inhibitor. Among these fatty acids, docosahexaenoic acid (DHA), a polyunsaturated fatty acid, exhibited the most potent Atg4B inhibitory activity. DHA inhibited autophagy induced by androgen receptor signaling inhibitors (ARSI) in LNCaP and 22Rv1 prostate cancer cells and significantly increased apoptotic cell death. Furthermore, we investigated the effect of DHA on resistance to ARSI by establishing darolutamide-resistant prostate cancer 22Rv1 (22Rv1/Dar) cells, which had developed resistance to darolutamide, a novel ARSI. At baseline, 22Rv1/Dar cells showed a higher autophagy level than parental 22Rv1 cells. DHA significantly suppressed Dar-induced autophagy and sensitized 22Rv1/Dar cells by inducing apoptotic cell death through mitochondrial dysfunction. These results suggest that DHA supplementation may improve prostate cancer therapy with ARSI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Biochemistry, Department of Biopharmaceutical Sciences, Gifu Pharmaceutical University, Gifu, 501-1196, Japan.
- Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, 565-0871, Japan.
- Center for Biosystems Dynamics Research, RIKEN, Kanagawa, 230-0045, Japan.
- Laboratories of Drug Informatics, Department of Pharmacy Practice and Science, Gifu Pharmaceutical University, Gifu, 501-1196, Japan.
- Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582, Japan.
- Department of Urology, University of Occupational and Environmental Health, Fukuoka, 807-8555, Japan.
Zitieren
APA
Kudo, Y., Nakamura, K., Tsuzuki, H., Hirota, K., Kawai, M., Takaya, D., Fukuzawa, K., Honma, T., Yoshino, Y., Nakamura, M., Shiota, M., Fujimoto, N., Ikari, A., & Endo, S. (2024). Docosahexaenoic acid enhances the treatment efficacy for castration-resistant prostate cancer by inhibiting autophagy through Atg4B inhibition. Archives of Biochemistry and Biophysics. https://doi.org/10.1016/j.abb.2024.110135
Vancouver
Kudo Y, Nakamura K, Tsuzuki H, Hirota K, Kawai M, Takaya D, et al. Docosahexaenoic acid enhances the treatment efficacy for castration-resistant prostate cancer by inhibiting autophagy through Atg4B inhibition. Archives of Biochemistry and Biophysics. 2024. doi:10.1016/j.abb.2024.110135
BibTeX
@article{Kudo2024,
author = {Kudo, Yudai and Nakamura, Kana and Tsuzuki, Honoka and Hirota, Kotaro and Kawai, Mina and Takaya, Daisuke and Fukuzawa, Kaori and Honma, Teruki and Yoshino, Yuta and Nakamura, Mitsuhiro and Shiota, Masaki and Fujimoto, Naohiro and Ikari, Akira and Endo, Satoshi},
title = {Docosahexaenoic acid enhances the treatment efficacy for castration-resistant prostate cancer by inhibiting autophagy through Atg4B inhibition},
journal = {Archives of Biochemistry and Biophysics},
year = {2024},
doi = {10.1016/j.abb.2024.110135}
}
EUVIMED